A novel diblock copolymer combines a small glycerol-based hydrophilic block (1–10 glycerol subunits) with a superhydrophobic perfluoro ether block (≥20 carbon atoms), linked covalently. It forms highly stable, biocompatible droplets for W/O and W/O/W emulsions, eliminating thermal-stability and cross-contamination over the traditional commercial PEG-based surfactants.

1.         Innovation Explanation:

The first block is a glycerol block comprising 1 to 10 subunits, optionally substituted, ideally 3–10 and often branched, providing hydrophilicity and biocompatibility. The second block is a superhydrophobic block with ≥20 carbon atoms, ≥40% fluorination, typically a PFPE residue. Linkers (amines, ethers, amides, alkyl chains) covalently join head and tail. Manufacturing employs acid-chloride activation of PFPE and amide or click chemistry with protected oligoglycerol amines. The diblock self-assembles at aqueous/oil interfaces into droplets that remain monodisperse after PCR cycles at ~98 °C and resist molecular exchange over 72 h. Cell viability assays show >90% survival within droplets, matching bulk culture.

Key Innovation Features and Advantages:

• Controlled two-block stoichiometric synthesis eliminates batch-to-batch variation, a key limitation commonly observed in commercial PEG-PFPE triblock systems. Exceptional thermal stability maintains droplet integrity during high-temperature assays.
• Ultra-low cross-contamination guarantees reliable assay performance in droplet based microfluidic.Potential Uses

• High-throughput droplet PCR for single-cell DNA analysis.
• Droplet-based drug screening with minimal reagent crossover.
•  Microgel particle templating for material synthesis.

Commercial Opportunities:

• Licensing opportunities with companies that manufacture and sell microfluidic devices..
• Specialty PFPE surfactant product lines for biotech markets.
• Custom droplet assay kits for pharma and diagnostics.

Current Status: Published (WO 2019/020626 A1); validated in lab-scale experiments. Scale-up and commercial partnerships under negotiation.